SG11201408423XA - ACRYLAMIDE COMPOUNDS AS HISTAMINE H<sb>3</sb> RECEPTOR LIGANDS - Google Patents
ACRYLAMIDE COMPOUNDS AS HISTAMINE H<sb>3</sb> RECEPTOR LIGANDSInfo
- Publication number
- SG11201408423XA SG11201408423XA SG11201408423XA SG11201408423XA SG11201408423XA SG 11201408423X A SG11201408423X A SG 11201408423XA SG 11201408423X A SG11201408423X A SG 11201408423XA SG 11201408423X A SG11201408423X A SG 11201408423XA SG 11201408423X A SG11201408423X A SG 11201408423XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- hyderabad
- serene
- avenue
- chambers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3464CH2012 | 2012-08-23 | ||
| PCT/IN2012/000796 WO2014030170A1 (en) | 2012-08-23 | 2012-12-05 | Acrylamide compounds as histamine h3 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408423XA true SG11201408423XA (en) | 2015-01-29 |
Family
ID=54187093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408423XA SG11201408423XA (en) | 2012-08-23 | 2012-12-05 | ACRYLAMIDE COMPOUNDS AS HISTAMINE H<sb>3</sb> RECEPTOR LIGANDS |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9328092B2 (es) |
| EP (1) | EP2888243B1 (es) |
| JP (1) | JP5981654B2 (es) |
| KR (1) | KR101707343B1 (es) |
| CN (1) | CN104540812B (es) |
| AP (1) | AP2014008139A0 (es) |
| AU (1) | AU2012388383C1 (es) |
| BR (1) | BR112015001524B1 (es) |
| CA (1) | CA2878217C (es) |
| CY (1) | CY1118035T1 (es) |
| DK (1) | DK2888243T3 (es) |
| EA (1) | EA025136B1 (es) |
| ES (1) | ES2592819T3 (es) |
| HK (1) | HK1204620A1 (es) |
| HR (1) | HRP20161167T1 (es) |
| HU (1) | HUE030901T2 (es) |
| IL (1) | IL236437A (es) |
| LT (1) | LT2888243T (es) |
| ME (1) | ME02519B (es) |
| MX (1) | MX360001B (es) |
| PL (1) | PL2888243T3 (es) |
| PT (1) | PT2888243T (es) |
| RS (1) | RS55158B1 (es) |
| SG (1) | SG11201408423XA (es) |
| SI (1) | SI2888243T1 (es) |
| SM (1) | SMT201600336B (es) |
| WO (1) | WO2014030170A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11313246B2 (en) | 2016-11-30 | 2022-04-26 | General Electric Company | Gas turbine engine wash system |
| EP4251148A1 (en) | 2020-11-27 | 2023-10-04 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
| AU2023228096A1 (en) | 2022-03-02 | 2024-10-17 | Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. | Histamine h3 receptor antagonist and medical use thereof |
| CN116693446A (zh) | 2022-03-02 | 2023-09-05 | 杭州百诚医药科技股份有限公司 | 苯基脲类衍生物及其医药用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006527211A (ja) * | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼの阻害剤として使用するための１−アリール−４−（アリールオキシカルボニル）−ピペラジン誘導体 |
| US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| NZ550764A (en) * | 2004-06-02 | 2009-09-25 | Hoffmann La Roche | Naphthaline derivatives useful as histamine-3-receptor ligands |
| BRPI0512335A (pt) * | 2004-06-21 | 2008-03-04 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização |
| US7705025B2 (en) | 2004-08-23 | 2010-04-27 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| KR101047204B1 (ko) * | 2005-11-30 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | Ｈ3 조절제로서 사용하기 위한1,1-다이옥소-싸이오모폴린일 인돌일 메탄온 유도체 |
| MX2008014532A (es) | 2006-05-30 | 2008-11-27 | Hoffmann La Roche | Derivados de piperidinil pirimidinas. |
| AU2008280257A1 (en) * | 2007-07-25 | 2009-01-29 | F. Hoffmann-La Roche Ag | Benzofuran- and benzo[B]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
| ES2384414T3 (es) | 2007-09-06 | 2012-07-04 | Glaxo Group Limited | Derivado de piperazina que tiene afinidad por el receptor H3 de histamina |
| WO2009100120A2 (en) | 2008-02-04 | 2009-08-13 | Neurogen Corporation | Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines |
| CA2719985A1 (en) | 2008-03-31 | 2009-10-08 | Evotec Ag | Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
| WO2009135842A1 (en) | 2008-05-08 | 2009-11-12 | Evotec Neurosciences Gmbh | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
| SG188212A1 (en) * | 2010-09-02 | 2013-04-30 | Suven Life Sciences Ltd | Heterocyclyl compounds as histamine h3 receptor ligands |
-
2012
- 2012-12-05 WO PCT/IN2012/000796 patent/WO2014030170A1/en active Application Filing
- 2012-12-05 RS RS20160783A patent/RS55158B1/sr unknown
- 2012-12-05 PL PL12844650T patent/PL2888243T3/pl unknown
- 2012-12-05 SI SI201230707A patent/SI2888243T1/sl unknown
- 2012-12-05 PT PT128446507T patent/PT2888243T/pt unknown
- 2012-12-05 MX MX2015000064A patent/MX360001B/es active IP Right Grant
- 2012-12-05 DK DK12844650.7T patent/DK2888243T3/en active
- 2012-12-05 CA CA2878217A patent/CA2878217C/en active Active
- 2012-12-05 AP AP2014008139A patent/AP2014008139A0/xx unknown
- 2012-12-05 EA EA201590413A patent/EA025136B1/ru unknown
- 2012-12-05 LT LTEP12844650.7T patent/LT2888243T/lt unknown
- 2012-12-05 ME MEP-2016-190A patent/ME02519B/me unknown
- 2012-12-05 HU HUE12844650A patent/HUE030901T2/en unknown
- 2012-12-05 KR KR1020157001952A patent/KR101707343B1/ko active IP Right Grant
- 2012-12-05 JP JP2015528009A patent/JP5981654B2/ja active Active
- 2012-12-05 SG SG11201408423XA patent/SG11201408423XA/en unknown
- 2012-12-05 EP EP12844650.7A patent/EP2888243B1/en active Active
- 2012-12-05 CN CN201280075253.4A patent/CN104540812B/zh active Active
- 2012-12-05 US US14/419,474 patent/US9328092B2/en active Active
- 2012-12-05 AU AU2012388383A patent/AU2012388383C1/en active Active
- 2012-12-05 ES ES12844650.7T patent/ES2592819T3/es active Active
- 2012-12-05 BR BR112015001524-7A patent/BR112015001524B1/pt active IP Right Grant
-
2014
- 2014-12-24 IL IL236437A patent/IL236437A/en active IP Right Grant
-
2015
- 2015-06-02 HK HK15105257.0A patent/HK1204620A1/xx unknown
-
2016
- 2016-09-13 HR HRP20161167TT patent/HRP20161167T1/hr unknown
- 2016-09-22 CY CY20161100943T patent/CY1118035T1/el unknown
- 2016-09-23 SM SM201600336T patent/SMT201600336B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201903103VA (en) | Dual inhibitors of vista and pd-1 pathways | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201407233RA (en) | Ethylene oligomerization process | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201407596TA (en) | Conjugation reagents | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions |